Literature DB >> 17284535

The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.

Luke F Peterson1, Ming Yan, Dong-Er Zhang.   

Abstract

The 8;21 translocation is a major contributor to acute myeloid leukemia (AML) of the M2 classification occurring in approximately 40% of these cases. Multiple mouse models using this fusion protein demonstrate that AML1-ETO requires secondary mutagenic events to promote leukemogenesis. Here, we show that the negative cell cycle regulator p21(WAF1) gene is up-regulated by AML1-ETO at the protein, RNA, and promoter levels. Retroviral transduction and hematopoietic cell transplantation experiments with p21(WAF1)-deficient cells show that AML1-ETO is able to promote leukemogenesis in the absence of p21(WAF1). Thus, loss of p21(WAF1) facilitates AML1-ETO-induced leukemogenesis, suggesting that mutagenic events in the p21(WAF1) pathway to bypass the growth inhibitory effect from AML1-ETO-induced p21(WAF1) expression can be a significant factor in AML1-ETO-associated acute myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17284535      PMCID: PMC1885483          DOI: 10.1182/blood-2006-03-012575

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  79 in total

1.  Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.

Authors:  S Hayette; X Thomas; Y Bertrand; I Tigaud; M Callanan; A Thiebaut; C Charrin; E Archimbaud; J P Magaud; R Rimokh
Journal:  Leukemia       Date:  1997-10       Impact factor: 11.528

2.  Overexpression of cyclin E in acute myelogenous leukemia.

Authors:  H Iida; M Towatari; M Tanimoto; Y Morishita; Y Kodera; H Saito
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

3.  Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors.

Authors:  T Okuda; Z Cai; S Yang; N Lenny; C J Lyu; J M van Deursen; H Harada; J R Downing
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

4.  Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO.

Authors:  M Y Ahn; G Huang; S C Bae; H J Wee; W Y Kim; Y Ito
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

5.  Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1.

Authors:  L S Chuang; H I Ian; T W Koh; H H Ng; G Xu; B F Li
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

6.  The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family.

Authors:  T Gamou; E Kitamura; F Hosoda; K Shimizu; K Shinohara; Y Hayashi; T Nagase; Y Yokoyama; M Ohki
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

7.  Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation.

Authors:  M Asada; T Yamada; H Ichijo; D Delia; K Miyazono; K Fukumuro; S Mizutani
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

8.  Cyclin A1 expression in leukemia and normal hematopoietic cells.

Authors:  R Yang; T Nakamaki; M Lübbert; J Said; A Sakashita; B S Freyaldenhoven; S Spira; V Huynh; C Müller; H P Koeffler
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

9.  Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation.

Authors:  A Krämer; A Hochhaus; S Saussele; A Reichert; A Willer; R Hehlmann
Journal:  Leukemia       Date:  1998-06       Impact factor: 11.528

10.  Structure and expression of the human MTG8/ETO gene.

Authors:  J K Wolford; M Prochazka
Journal:  Gene       Date:  1998-05-28       Impact factor: 3.688

View more
  34 in total

1.  Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

Authors:  Heidi J Nick; Hyung-Gyoon Kim; Chia-Wei Chang; Kevin W Harris; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

2.  RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).

Authors:  R Katherine Hyde; P Paul Liu
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

3.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

4.  ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.

Authors:  Daniela Salat; Robert Liefke; Jörg Wiedenmann; Tilman Borggrefe; Franz Oswald
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

Review 5.  AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.

Authors:  Megan A Hatlen; Lan Wang; Stephen D Nimer
Journal:  Front Med       Date:  2012-08-09       Impact factor: 4.592

6.  Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.

Authors:  Miao-Chia Lo; Luke F Peterson; Ming Yan; Xiuli Cong; Fulai Jin; Wei-Jong Shia; Shinobu Matsuura; Eun-Young Ahn; Yukiko Komeno; Minh Ly; Hans B Ommen; I-Ming Chen; Peter Hokland; Cheryl L Willman; Bing Ren; Dong-Er Zhang
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

7.  Runx2 induces acute myeloid leukemia in cooperation with Cbfbeta-SMMHC in mice.

Authors:  Ya-Huei Kuo; Sayyed K Zaidi; Svetlana Gornostaeva; Toshihisa Komori; Gary S Stein; Lucio H Castilla
Journal:  Blood       Date:  2009-01-28       Impact factor: 22.113

Review 8.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

9.  Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.

Authors:  Kevin A Link; Shan Lin; Mahesh Shrestha; Melissa Bowman; Mark Wunderlich; Clara D Bloomfield; Gang Huang; James C Mulloy
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

10.  p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death.

Authors:  Ondrej Krejci; Mark Wunderlich; Hartmut Geiger; Fu-Sheng Chou; David Schleimer; Michael Jansen; Paul R Andreassen; James C Mulloy
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.